| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ... Annals of Oncology 26 (12), 2375-2391, 2015 | 1574 | 2015 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1367 | 2020 |
| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 1211 | 2021 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 831 | 2018 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 703 | 2018 |
| Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer BT Li, EF Smit, Y Goto, K Nakagawa, H Udagawa, J Mazières, ... New England Journal of Medicine 386 (3), 241-251, 2022 | 626 | 2022 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 591 | 2017 |
| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ... Nature medicine 25 (12), 1928-1937, 2019 | 570 | 2019 |
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 479 | 2018 |
| First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study RJ Sullivan, JR Infante, F Janku, DJL Wong, JA Sosman, V Keedy, ... Cancer discovery 8 (2), 184-195, 2018 | 381 | 2018 |
| Accelerating discovery of functional mutant alleles in cancer MT Chang, TS Bhattarai, AM Schram, CM Bielski, MTA Donoghue, ... Cancer discovery 8 (2), 174-183, 2018 | 321 | 2018 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 313 | 2020 |
| Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega, BT Li, A Drilon, MG Kris, ... Clinical Cancer Research 25 (3), 1063-1069, 2019 | 313 | 2019 |
| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 300 | 2020 |
| Diagnosis of gastrointestinal bleeding: A practical guide for clinicians BSM Kim, BT Li, A Engel, JS Samra, S Clarke, ID Norton, AE Li World journal of gastrointestinal pathophysiology 5 (4), 467, 2014 | 291 | 2014 |
| Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors J Tsurutani, H Iwata, I Krop, PA Jänne, T Doi, S Takahashi, H Park, ... Cancer discovery 10 (5), 688-701, 2020 | 287 | 2020 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ... Annals of Oncology 29 (10), 2085-2091, 2018 | 272 | 2018 |
| HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers BT Li, DS Ross, DL Aisner, JE Chaft, M Hsu, SL Kako, MG Kris, ... Journal of Thoracic Oncology 11 (3), 414-419, 2016 | 263 | 2016 |
| Diverse alterations associated with resistance to KRAS (G12C) inhibition Y Zhao, YR Murciano-Goroff, JY Xue, A Ang, J Lucas, TT Mai, ... Nature 599 (7886), 679-683, 2021 | 240 | 2021 |
| Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance HA Yu, K Suzawa, E Jordan, A Zehir, A Ni, R Kim, MG Kris, MD Hellmann, ... Clinical Cancer Research 24 (13), 3108-3118, 2018 | 229 | 2018 |
